Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial

Article Details

Citation

Copy to clipboard

de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial

Neuro-oncology.

PubMed ID

Not Available

Abstract

Not Available

DrugBank Data that Cites this Article

Drugs

Olutasidenib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Olutasidenib	Isocitrate dehydrogenase [NADP] cytoplasmic	Protein	Humans	Yes	Inhibitor	Details